- Home Page
- Sales & Partners
- News & Events
- Site Map
|Method & Line||Sample & Target||Product||Package Info|
|IMMUNOgen - Immunoassays||Plasma,Serum||GI-Marker CA 19-9||Tests per Package: 100|
|IMMUNOgen||The Eclectica GI Marker CA 19-9 assay for the Eclectica and Eclectica TiCA analysers has been designed for the quantitative determination of gastrointestinal cancer associated antigen CA 19-9 in human serum and heparinized plasma. The method can be used without dilution for samples containing 2 - 400 U/ml (U = arbitrary units : there is no internationally recognized standard for the measurement of CA 19-9).||Code: 1705300||Package: 2 x 50|
Please pay attention to the revision of the document that must be the same as the revision reported in the box label.
In case of discrepancy please contact our Customer Care e-mail: email@example.com.
* Other document related to the product available at Documentation Centre and it is accessible for Adaltis distributors/partners after registration only.
The Eclectica GI Marker CA 19-9 assay for the Eclectica analyzers has been designed for the quantitative determination of gastrointestinal cancer associated antigen CA 19-9 in human serum and heparinized plasma. The method can be used without dilution for samples containing 2-400 U/ml (U = arbitrary units: there is no internationally recognized standard for the measurement of CA 19-9).
The CA 19-9 is a carbohydrate antigen predominantly associated with gastrointestinal (GI) malignancies; pancreatic, colorectal, gastric and hepatic carcinomas (1-2-3). The main application of CA 19-9 is in the management of diagnosed pancreatic and colorectal cancers (4-5-6). The CA 19-9 was detected by Koprowski (Wistar Institute) using a monoclonal antibody (1116 NS - 19-9) directed against a human colorectal cancer cell line and obtained by Immunization of Balb/c mice. Immunochemically, CA 19-9 antigen is the sialated form of the blood group antigen Lewis (7-8). Clinical studies indicate that CA 19-9 assay levels have been found elevated in the serum with carcinomas of the exocrine pancreas, the colon and rectum, the stomach and lung cancer (9-10-11).
In non malignant gastrointestinal disorders, elevation of CA 19-9 is less common than that of CEA (12-13-14). The CA 19-9 concentration should always be interpreted taking into consideration other clinical data and should not be used as a cancer screening test.
The CA 19-9 values are defined by using the same monoclonal antibody to CA 19-9 (C 192) in both positions of the sandwich (capture and detection antibody).
The C 192 hybridoma was established by immunization of Balb/c mice with the human colorectal adenocarcinoma cell-line COLO 205 and fusion with the Sp2/0 myeloma cell line. The C 192 MAb reacts specifically with Sialyl Lewisa epitopes of the CA 19-9 antigen.
The Eclectica GI Marker CA 19-9 assays for the Eclectica analyzers consists of:
In the Eclectica GI Marker CA 19-9 assay, two high affinity monoclonal antibodies are used in an immunoenzymetric assay system which incorporates magnetic solid phase separation. All incubation times and reagent volumes are determined by an assay specific software protocol.
Fixed amounts of fluorescein-conjugated anti-CA 19-9 monoclonal antibody and anti-CA 19-9 monoclonal antibody conjugated to alkaline phosphatase are added to a sample, control, or standard. The reactants are incubated at 37°C. During the incubation fluorescein-anti-CA 19-9 monoclonal antibody binds to a discrete site on the CA 19-9 antigen molecule. Alkaline phosphatase anti-CA 19-9 monoclonal antibody binds to a second site on the CA 19-9 antigen forming a sandwich.
At the end of the incubation period anti-fluorescein coupled to a magnetic solid phase is added in excess. This rapidly and specifically binds to the CA 19-9 monoclonal antibody complex and is sedimented in a magnetic field.
After aspirating the liquid phase and washing the solid phase, a solution of the enzyme substrate, phenolphthalein monophosphate is added to the incubation cell and the each cell incubated at 37°C. After incubation the enzyme reaction is stopped by the addition of a stop reagent and the intensity of the color developed is measured photometrically. The intensity of the color developed is directly proportional, within the working range of the assay, to the concentration of CA 19-9 antigen in the sample. The concentration of CA 19-9 antigen in a patient sample or control is then determined by interpolation from a stored standard curve.
Eclectica GI Marker CA 19-9 Reagent Kit
Eclectica GI Marker CA 19-9 Calibration Kit
Eclectica Diluent 2 Kit
Eclectica Immunoassay Common Reagents Kit
Eclectica Immunoassay Wash Solution
Eclectica Systemic Wash Solution
1700006 Eclectica Cleaning Kit